SDC1 and Miyoshi myopathy: Chérel and colleagues showed promising therapeutic efficacy of 213Bi-labeled anti-mouse CD138 for the treatment of residual disease in MM, with only moderate and transient toxicity (166), though a study comparing B-B4-I131 and B-B4-Bi213 demonstrated that the latter showed significantly higher efficacy in terms of cell viability, blockade of G2/M phase and clonogenic survival in MM cell lines (165).